Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea
Singapore-based firm last valued at US$827m; does not say how much it is raising in IPO
Add BT as a preferred source
Singapore
SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).
Earlier on Friday, BT reported that Prestige Biopharma's Singapore-registered entity had been been fully acquired by the Korea Securities Depository (KSD), as shown in Dec 8 regulatory data on intelligence platform VentureCap Insights.
TRENDING NOW
Simba ordered to pay S$700,000 in damages to indoor skydiving operator Altitude Xperience for trespass
Singapore banks may need to address indirect exposure to captive coal in their financing policies
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
EU and Asean at 50: time for bold action
